Technology ID

SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies

Lead Inventor
Graham, Barney (NIAID)
Wang, Lingshu (NIAID)
Mascola, John (NIAID)
Corbett, Kizzmekia (NIAID)
Research Materials
Therapeutic Areas
Infectious Disease
Development Status
Research material
Research Products
Lead IC

NIAID scientists have developed plasmids that allow for production of pseudoviruses expressing SARS-CoV-2 spike protein. As SARS-CoV-2 is a lethal airborne virus, it must be handled in high-containment Biosafety Level 3 (BSL-3) laboratories that require strict airflow, ventilation and decontamination procedures. The pseudotyping plasmids of this invention provide a secure platform for exploring SARS-CoV-2 dynamics without the need for high-risk handling of live virus and ensure a controlled environment for scientists to study SARS-CoV-2 more expeditiously in standard Biosafety Level 2 (BSL -2) laboratories. The plasmids can be used for diverse SARS-CoV-2 research applications, including the study of newly emerging or potential future variants of interest.

Commercial Applications
  • Research material that can be used in the development of neutralization assays
Competitive Advantages
  • Expedite SARS-CoV-2 related experiments by enabling them to be conducted in laboratories with a lower Biosafety Level (BSL-2) than that required for handling SARS-CoV-2 (BSL-3)